Here, the findings position VPS37A deficiency as both a prognostic biomarker and an actionable metabolic liability in CRC, establishing TNFR1/NF-κB pathway inhibition as a tailored therapeutic strategy for CRC patients. This evidence concerns the gene VPS37A and colorectal carcinoma.